Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.48 USD
-0.10 (-1.17%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $8.47 -0.01 (-0.12%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Brokerage Reports
Theravance Biopharma, Inc. [TBPH]
Reports for Purchase
Showing records 81 - 100 ( 209 total )
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Strong 3Q for Yupelri Though TD-8236 Hits a Speed Bump as Important Readouts Approach in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Yupelri Holds up Despite Covid-19 Headwinds, Key Readouts Near; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Theravance Biopharma, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department